Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly improve outcomes for patients with colorectal peritoneal metastases.

• Median overall survival with complete cytoreductive clearance is 43 months, compared to 10-18 months with systemic chemotherapy alone.
• Patients with the KRAS G12V mutation have a median overall survival of 34 months, significantly lower than the wild-type group (p = 0.04).

This highlights the importance of molecular profiling in optimizing patient selection and surgical strategies to enhance outcomes.

• BRAF V600E mutation predicts a median disease-free survival of only 9 months (p = 0.02).